NCT06222853View on ClinicalTrials.gov

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 10, 2024

Primary Completion Date

April 4, 2025

Study Completion Date

December 30, 2026

Conditions
Systemic Lupus ErythematosusCAR-T Cell Therapy
Interventions
BIOLOGICAL

anti-CD19-CAR-T cells

Three dose groups (0.3×10\^5/kg, 1×10\^5/kg, 3×10\^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Trial Locations (1)

310052

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Chongqing Precision Biotech Co., Ltd

INDUSTRY

lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER

NCT06222853 - Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter